Objective: To evaluate the expression of activating and inhibitory Fc-gamma receptors (FcgRs) before and during clinically effective therapy with IV immunoglobulin (IVIg) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Humoral immune responses, which link innate and adaptive immunity, are believed to play a central role in mediating peripheral nerve injury and represent important therapeutic targets in chronic inflammatory demyelinating polyneuropathy (CIDP). Both sera and immunoglobulin G (IgG) molecules from patients with CIDP induce peripheral demyelination in susceptible animals 1 and inhibit nerve conduction in several models of peripheral neuropathies. 2 Plasma exchange therapy, i.e., removal of humoral immune factors, as well as IV immunoglobulin (IVIg) are first-line therapies in patients with CIDP. 3, 4 IgG-mediated effector functions are mediated through interaction of the antibodies' Fc fragment with cellular Fc-gamma receptors (FcgRs) expressed by innate immune cells and B lymphocytes. 5, 6 The family of FcgRs consists of several activating members (FcgRIA, IIA, IIC, and IIIA in humans) and one inhibitory member (FcgRIIB). FcgR-mediated effector functions are determined by signals derived from both activating and inhibitory FcgRs since both classes of receptors are expressed by most hematopoietic cells. [5] [6] [7] [8] We previously reported that compared with demographically matched healthy controls, patients with CIDP showed lower FcgRIIB
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1 B cells and, in some patients, on CD14 1 monocytes and following IVIg treatment. 9 Here, we investigated the expression profile of activating and inhibitory FcgRs in patients with CIDP before and during IVIg therapy.
METHODS Patients. Patients with CIDP (n 5 24) and healthy controls matched by age and sex (n 5 19) were recruited between 2010 and 2013 at the Department of Neurology, University of Marburg, Germany (table). All patients fulfilled the European Federation of Neurological Societies/ Peripheral Nerve Society diagnostic criteria for CIDP. They were prospectively followed during IVIg therapy (2 g/kg over 5 days) using the modified Rankin Scale to monitor clinical treatment response.
9,10 Improvement on the modified Rankin Scale within 4 weeks after IVIg treatment was defined as a positive treatment response. Patients did not receive IVIg therapy or immunosuppressive treatment including corticosteroids before study entry. Peripheral blood mononuclear cell samples were collected at each visit and obtained before, 2 weeks after, and 8 weeks after treatment with IVIg.
Standard protocol approvals, registrations, and patient consents. The university's institutional review board approved the study according to the Declaration of Helsinki, good clinical practice, and German law (file reference 46/00). Studies in several mouse autoimmune disease models demonstrated that the anti-inflammatory activity of Age, y, mean 6 SD (range) 59.0 6 9.4 (36-72) 58.7 6 9.1 (34-74)
Male to female ratio 3 5
Fulfilling modified AAN criteria, n (%) 24 (100) NA IVIg requires the presence and upregulation of the inhibitory FcgRIIB.
11-13
Here, we analyzed expression levels of FcgRIIB compared with the activating FcgRI and FcgRIIA in patients with CIDP before as well as 2 and 4-8 weeks following IVIg therapy. The clinical response rate to IVIg therapy was 87.5%, as defined by an improvement in disability within 4 weeks after IVIg therapy. . None of the patients with a clinical response to the first dose of IVIg (2 g/kg for 2-3 days) deteriorated before initiation of maintenance therapy (1 g/kg for 1-2 days), which was started 4-8 weeks after the first dose of IVIg, suggesting that sustained upregulation of FcgRIIB after 4-8 weeks is associated with a clinical response to IVIg therapy. Three patients did not show improvement on the modified Rankin Scale 4 weeks after the first course of IVIg therapy. These patients received a second course of IVIg therapy based on observations that some patients require at least 2 courses of IVIg to determine whether they are responding to treatment. 13, 15 Indeed, these patients improved after a second course of IVIg therapy and thereafter received long-term maintenance therapy. FcgIIB expression was also upregulated on naive and memory B cells in those patients with an initially poor response to IVIg ( figure 2) levels of the low-affinity activating FcgRIIA were not significantly regulated by IVIg therapy ( figure 2C ).
DISCUSSION Balanced signaling through activating and inhibitory FcgRs regulates innate and adaptive immune responses, and impairment of the FcgR regulatory system is associated with an increased susceptibility to autoimmune disease. 5 Mice deficient in activating FcgR signaling are resistant to the induction of various autoimmune disease models. Mice lacking the inhibitory FcgRIIB spontaneously develop autoimmune disorders, 16 and restoration of decreased FcgRIIB expression on activated B cells in autoimmune-susceptible mice restores immunologic tolerance. 6 We found that patients with CIDP show increased expression levels of the activating FcgRI and FcgRIIA on monocytes but decreased expression levels of the inhibitory FcgRIIB on monocytes and B cells. IVIg therapy partially restored deregulated FcgR expression levels.
Nonfunctional FcgRIIB variants or decreased FcgRIIB expression have been shown to be associated with the development and severity of systemic lupus erythematosus (SLE). 6, 17 In line with our previous study in an independent cohort of patients with CIDP, we found that untreated patients with CIDP show lower FcgRIIB expression levels on naive and memory B cells and fail to upregulate or maintain upregulation of FcgRIIB as B cells progressed from the naive to the memory compartment. 9 In addition, monocyte expression of FcgRIIB is impaired in patients with CIDP. A potential explanation for the lower expression levels of FcgRIIB is functionally relevant single nucleotide polymorphisms in the FcgRIIB promoter, which are associated with autoimmune phenotypes 9, [18] [19] [20] and increased in frequency in patients with CIDP. 9 Increased monocyte expression of the activating FcgRI was recently identified as a potential biomarker for disease activity in patients with SLE and rheumatoid arthritis (RA), in whom monocyte expression levels of FcgRI are significantly higher in active disease compared with inactive disease. 21 Our data indicate that deregulated monocyte expression of FcgRI is not confined to patients with SLE and RA. FcgRI expression is induced by interferon-a (IFN-a) , among other cytokines, and increased FcgRI levels on monocytes derived from patients with SLE were attributed to higher IFN-a production in these patients. 21 A role for IFN-a in the pathogenesis of CIDP is less well established, although some studies report increased levels of type I IFN signaling in patients with CIDP 22 or development of CIDP associated with IFN-a therapy. [23] [24] [25] [26] [27] [28] [29] Activation of FcgRI on monocytes triggers differentiation into immature dendritic cells that induce autoreactive T cell responses and has therefore been implicated in mediating tissue injury in antibody-mediated autoimmune diseases. 30 FcgRI-mediated activation and differentiation of myeloid cells might also contribute to peripheral nerve damage in CIDP, where myeloid cells are believed to be the main local effector cells. 2 The analysis of concomitant expression of activating and inhibitory FcgRs indicates that the FcgR regulatory system, rather than expression levels of a single receptor, is disturbed in patients with CIDP. Altogether, these data suggest that deregulated expression of activating vs inhibitory FcgR expression might lower the activation threshold for myeloid cells and B cells, 7, 8 thereby contributing to susceptibility to CIDP. 5 In animal models of immune thrombocytopenic purpura, RA, and nephrotoxic nephritis, IVIg administration results in an upregulation of FcgRIIB surface expression on effector macrophages or enhanced recruitment of FcgRIIB-expressing myeloid cells at the site of inflammation in vivo. 11, 31, 32 Moreover, the clinical efficacy of IVIg therapy was shown to be dependent on the presence of the inhibitory FcgRIIB. 31 Our data suggest that restoration of deregulated activating vs inhibitory FcgR expression might contribute to the clinical efficacy of IVIg in patients with CIDP. Notably, upregulation of the inhibitory FcgRIIB on B cells and downmodulation of the activating FcgRI on CD14 low CD16
1 inflammatory monocytes were stronger after 2 weeks compared with 4-8 weeks in most patients, suggesting that a single treatment course of IVIg does not lead to sustained restoration of FcgR expression levels in patients with CIDP.
There are limitations to our study. First, due to the relatively small number of patients and the high response rate to IVIg therapy, patients were not stratified for disease severity and treatment response. FcgR expression profiling could potentially assist in the development of biomarkers indicative of disease activity and treatment response, 33 but this requires validation in larger independent cohorts. Second, we did not monitor FcgR levels beyond 8 weeks following therapy. Repeated infusions of IVIg are generally necessary to maintain a clinical benefit, 4, 15 and it is tempting to speculate that FcgR expression levels might return to pretreatment levels beyond an observation period of 8 weeks. Nevertheless, our findings should provide incentive to conduct larger prospective investigations to examine FcgR expression in leukocyte subsets in patients with CIDP.
Our study provides evidence for a deregulated FcgR expression profile in treatment-naive patients with CIDP that might contribute to disease susceptibility. The validity of FcgR expression profiling as a biomarker for disease progression and treatment response remains to be evaluated. Therapeutic strategies that aim at balancing deregulated FcgR expression levels might provide a clinical benefit for patients with CIDP.
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